Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

April 6, 2021

Study Completion Date

April 6, 2021

Conditions
Pneumococcal Infection
Interventions
BIOLOGICAL

V116

Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

BIOLOGICAL

PNEUMOVAX™23

Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Trial Locations (2)

812-0025

Souseikai PS Clinic ( Site 0201), Fukuoka

861-4157

Souseikai Nishikumamoto Hospital ( Site 0202), Kumamoto

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04665050 - Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) | Biotech Hunter | Biotech Hunter